IBDEI0IY ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,8528,1,3,0)
 ;;=3^Carcinoma in Situ of Endocervix
 ;;^UTILITY(U,$J,358.3,8528,1,4,0)
 ;;=4^D06.0
 ;;^UTILITY(U,$J,358.3,8528,2)
 ;;=^5001938
 ;;^UTILITY(U,$J,358.3,8529,0)
 ;;=D06.1^^39^401^48
 ;;^UTILITY(U,$J,358.3,8529,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8529,1,3,0)
 ;;=3^Carcinoma in Situ of Exocervix
 ;;^UTILITY(U,$J,358.3,8529,1,4,0)
 ;;=4^D06.1
 ;;^UTILITY(U,$J,358.3,8529,2)
 ;;=^5001939
 ;;^UTILITY(U,$J,358.3,8530,0)
 ;;=D06.7^^39^401^46
 ;;^UTILITY(U,$J,358.3,8530,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8530,1,3,0)
 ;;=3^Carcinoma in Situ of Cervix,Other Parts
 ;;^UTILITY(U,$J,358.3,8530,1,4,0)
 ;;=4^D06.7
 ;;^UTILITY(U,$J,358.3,8530,2)
 ;;=^5001940
 ;;^UTILITY(U,$J,358.3,8531,0)
 ;;=D04.9^^39^401^49
 ;;^UTILITY(U,$J,358.3,8531,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8531,1,3,0)
 ;;=3^Carcinoma in Situ of Skin
 ;;^UTILITY(U,$J,358.3,8531,1,4,0)
 ;;=4^D04.9
 ;;^UTILITY(U,$J,358.3,8531,2)
 ;;=^5001925
 ;;^UTILITY(U,$J,358.3,8532,0)
 ;;=C91.11^^39^401^52
 ;;^UTILITY(U,$J,358.3,8532,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8532,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,In Remission
 ;;^UTILITY(U,$J,358.3,8532,1,4,0)
 ;;=4^C91.11
 ;;^UTILITY(U,$J,358.3,8532,2)
 ;;=^5001766
 ;;^UTILITY(U,$J,358.3,8533,0)
 ;;=C91.10^^39^401^53
 ;;^UTILITY(U,$J,358.3,8533,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8533,1,3,0)
 ;;=3^Chronic Lymphocytic Leukemia of B-Cell Type,Not in Remission
 ;;^UTILITY(U,$J,358.3,8533,1,4,0)
 ;;=4^C91.10
 ;;^UTILITY(U,$J,358.3,8533,2)
 ;;=^5001765
 ;;^UTILITY(U,$J,358.3,8534,0)
 ;;=C92.11^^39^401^54
 ;;^UTILITY(U,$J,358.3,8534,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8534,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,In Remission
 ;;^UTILITY(U,$J,358.3,8534,1,4,0)
 ;;=4^C92.11
 ;;^UTILITY(U,$J,358.3,8534,2)
 ;;=^5001793
 ;;^UTILITY(U,$J,358.3,8535,0)
 ;;=C92.10^^39^401^55
 ;;^UTILITY(U,$J,358.3,8535,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8535,1,3,0)
 ;;=3^Chronic Myeloid Leukemia,BCR/ABL-Positive,Not in Remission
 ;;^UTILITY(U,$J,358.3,8535,1,4,0)
 ;;=4^C92.10
 ;;^UTILITY(U,$J,358.3,8535,2)
 ;;=^5001792
 ;;^UTILITY(U,$J,358.3,8536,0)
 ;;=D47.1^^39^401^56
 ;;^UTILITY(U,$J,358.3,8536,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8536,1,3,0)
 ;;=3^Chronic Myeloproliferative Disease
 ;;^UTILITY(U,$J,358.3,8536,1,4,0)
 ;;=4^D47.1
 ;;^UTILITY(U,$J,358.3,8536,2)
 ;;=^5002256
 ;;^UTILITY(U,$J,358.3,8537,0)
 ;;=C82.69^^39^401^57
 ;;^UTILITY(U,$J,358.3,8537,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8537,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,8537,1,4,0)
 ;;=4^C82.69
 ;;^UTILITY(U,$J,358.3,8537,2)
 ;;=^5001530
 ;;^UTILITY(U,$J,358.3,8538,0)
 ;;=C82.60^^39^401^58
 ;;^UTILITY(U,$J,358.3,8538,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8538,1,3,0)
 ;;=3^Cutaneous Follicle Center Lymphoma,Unspec Site
 ;;^UTILITY(U,$J,358.3,8538,1,4,0)
 ;;=4^C82.60
 ;;^UTILITY(U,$J,358.3,8538,2)
 ;;=^5001521
 ;;^UTILITY(U,$J,358.3,8539,0)
 ;;=D56.2^^39^401^59
 ;;^UTILITY(U,$J,358.3,8539,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8539,1,3,0)
 ;;=3^Delta-Beta Thalassemia
 ;;^UTILITY(U,$J,358.3,8539,1,4,0)
 ;;=4^D56.2
 ;;^UTILITY(U,$J,358.3,8539,2)
 ;;=^340496
 ;;^UTILITY(U,$J,358.3,8540,0)
 ;;=D75.9^^39^401^60
 ;;^UTILITY(U,$J,358.3,8540,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,8540,1,3,0)
 ;;=3^Disease of Blood/Blood-Forming Organs,Unspec
